Henrik Landgren

Company: Abbvie

Job title: Scientific Director, Precision Medicine Immunology & Fibrosis

Seminars:

Panel Discussion: Clinical Perspectives on Positioning Antifibrotics in a Post-GLP-1 World 5:00 pm

As GLP-1 receptor agonists continue to redefine the treatment landscape for metabolic diseases, antifibrotic developers face mounting pressure to demonstrate clinical value beyond metabolic control. This panel explores the evolving expectations for antifibrotic therapies in MASH and beyond, as well as the implications of real-world GLP-1 usage. Key Questions for Discussion: Who are the patients…Read more

day: Conference Day One

The Big Debate: Pan-Antifibrotics, Fact or Fiction? Dissecting Mechanisms & Organ Specificity & Strategies for Cross-Tissue Success 2:00 pm - 4:00 pm

As interest grows in developing antifibrotics with cross-indication potential, this workshop critically examines whether a true “pan-antifibrotic” is biologically and clinically feasible. Through real-world data, mechanistic comparisons, and forward-looking trial design strategies, we’ll explore what it would take to deliver a truly universal fibrosismodifying therapy. This workshop will gather experts to discuss: Reviewing trials of…Read more

day: Pre-Conference Day